{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00169",
      "entity_text" : "hIL6R",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ],
      "TissueType" : [ "tissuelist:TS-0800" ],
      "Organ" : [ "uberon:UBERON:0001130" ]
    }
  },
  "verbose_text" : "We consider that increased plasma levels of soluble hIL6R and human IL6 in tocilizumab treated Il6ra hIL6R / hIL6R -hIL6 transgenic mice could be caused by a mechanism similar to that in humans, and that our humanized Castleman 's disease model would substantially reflect the clinical outcomes seen in the tocilizumab treated patients.",
  "reading_complete" : "2020-08-04T09:02:52Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T09:01:17Z",
  "trigger" : "levels",
  "evidence" : [ "levels of soluble hIL6R" ],
  "pmc_id" : "3561642",
  "score" : 0
}